Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific cytotoxic T-lymphocyte activities

Virology

Volumn 236, Issue 2, 1997, Pages 307-315

  Tobin, Gregory J ^a   Li, Grace H ^a   Fong, Steven E ^a   Nagashima, Kunio ^a   Gonda, Matthew A ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; INSECT; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; VIRUS PARTICLE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INSECTA;

EID: 0030866324     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8745     Document Type: Article

References (57)

1. Adams S. E., Dawson K. M., Gull K., Kingsman S. M., Kingsman A. J. The expression of hybrid HIV:Ty virus like particles in yeast. Nature (London). 329:1987;68-70.
2. Adams S. E., Vyakarnam A., Cheingsong-Popov R., Callow D., Jones K. L., Senior J. M., Kingsman A. J., Matear P., Cotch F. M., McMichael A. J., Roitt I. M., Weber J. N. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS. 7:1993;1315-1323.
3. Birx D. L., Redfield R. R. Immunotherapeutic strategies in the treatment of HIV infection and AIDS. Curr. Opin. Immunol. 5:1993;600-607.
4. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
5. Burke D. S. Vaccine therapy for HIV: A historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. Vaccine. 11:1993;883-891.
6. Cao Y., Qin L., Zhang L., Safrit J., Ho D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:1995;201-208.
7. Cheynier R., Langlade-Demoyen P., Marescot M. R., Blanche S., Blondin G., Wain-Hobson S., Griscelli C., Vilmer E., Plata F. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur. J. Immunol. 22:1992;2211-2217.
8. Clerici M., Giorgi J. V., Chou S., Gudeman V. K., Zack J. A., Gupta P., Ho H., Nishanian P. G., Berzofsky J. A., Shearer G. M. Cell-mediated imune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 165:1992;1012-1019.
9. Clerici M., Sison A. V., Berzofsy J. A., Rakusan T. A., Brandt C. D., Ellaurie M., Villa M., Collie C., Venzon D. L., Sever J. L., Shearer G. M. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS. 7:1993;1427-1433.
10. Coligan J. E., Kruisbeek A. M., Margulies D. H., Shevach E. M., Strober W. Current Protocols in Immunology. 1:1994;Wiley-Interscience, New York.
11. Daar E. S., Moudgil T., Meyer R. D., Ho D. D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:1991;961-964.
12. Delchambre M., Gheysen D., Thines D., Thiriart C., Jacobs E., Verdin E., Horth M., Burny A., Bex F. The Gag precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J. 8:1989;2653-2660.
13. Ferbas J., Kaplan A. H., Hausner M. A., Hultin L. E., Matud J. L., Liu Z., Panicali D. L., Nerng-Ho H., Detels R., Giorgi J. V. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J. Infect. Dis. 172:1995;329-339.
14. gag. Cell. 59:1989;103-112.
15. Graziosi C., Pantaleo G., Butini L., Demarest J. F., Saag M. S., Shaw G. M., Fauci A. S. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA. 90:1993;6405-6409.
16. Griffiths J. C., Berrie E. L., Holdsworth L. N., Moore J. P., Harris S. J., Senior J. M., Kingsman S. M., Kingsman A. J., Adams S. E. Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty virus-like particles in a clinically relevant adjuvant. J. Virol. 65:1991;450-456.
17. Griffiths J. C., Harris S. J., Layton G. T., Berrie E. L., French T. J., Burns N. R., Adams S. E., Kingsman A. J. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 67:1993;3191-3198.
18. Harrer T., Harrer E., Kalams S. A., Barbosa P., Trocha A., Johnson R. P., Elbeik T., Feinburg M. B., Buchbinder S. P., Walker B. D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 156:1996;2616-2623.
19. Hilleman M. R. The dilemma of AIDS vaccine and therapy: Possible clues from comparative pathogenesis with measles. AIDS. Res. Hum. Retroviruses. 8:1992;1743-1747.
20. Ho D. D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321:1989;1621-1625.
21. Hoth D. F., Bolognesi D. P., Corey L., Vermund S. H. NIH conference: HIV vaccine development: A progress report. Ann. Intern. Med. 121:1994;603-611.
22. Hu S. L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 255:1992;456-459.
23. Karacostas V., Nagashima K., Gonda M. A., Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc. Natl. Acad. Sci. USA. 86:1989;8964-8967.
24. Klein M. R., van Baalen C. A., Holwerday A. M., Kerkhof Garde S. R., Bende R. J., Keet I. P., Eeftinck-Schattenkerk J. K., Osterhaus A. D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1995;1365-1372.
25. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
26. Krausslich H. G., Ochsenbauer C., Traenckner A.-M., Mergener K., Facke M., Gelderblom H. R., Bosch V. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology. 192:1993;605-617.
27. Layton G. T., Harris S. J., Gearing A. J., Hill-Perkins M., Cole J. S., Griffiths J. C., Burns N. R., Kingsman A. J., Adams S. E. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151:1993;1097-1107.
28. Layton G. T., Jarris S. L., Myhan J., West D., Gotch F., Hill-Perkins M., Cole J. S., Meyers N., Woodrow S., French T. J., Adams S. E., Kingsman A. J. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology. 87:1996;171-178.
29. Levy J. A. HIV pathogenesis and long-term survival. AIDS. 7:1993a;1401-1410.
30. Levy J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:1993b;183-289.
31. Lori F., Hall L., Lusso P., Popovic M., Markham P., Franchini G., Reitz M. S. Jr. Effect of Reciprocal-complementation of two defective human immunodeficiency virus Type I (HIV-1) Molecular clones on HIV-1 tropism and virulence. J. Virol. 66:1992;5553-5560.
32. Luo L., Li Y., Kang C. Y. Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells. Virology. 179:1990;874-880.
33. Luo L., Li Y., Cannon P. M., Kim S., Kang C. Y. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 89:1992;10527-10531.
34. Martin S. J., Vyakarnam A., Cheingsong-Popov R., Callow D., Jones K. L., Senior J. M., Adams S. E., Kingsman A. J., Matear P., Gotch F. M., McMichael A. J., Roiff M., Weber J. N. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS. 7:1993;1315-1323.
35. Mellors J. W., Rinaldo C. R. Jr., Gupta P., White R. M., Todd J. A., Kingsley L. A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
36. Michael N. L., Burke D. S. Natural history of human immunodeficiency virus infection. Dermatol. Clin. North Am. 9:1991;429-441.
37. Morikawa S., Booth T. F., Bishop D. H. L. Analysis of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors. Virology. 183:1991;288-297.
38. Pantaleo G., Demarest J. F., Soudeyns H., Graziosi C., Denis F., Adelsberger J. W., Borrow P., Saag M. S., Shaw G. M., Sekaly R. P., Fauci A. S. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (London). 370:1994;463-467.
39. Parkin N. T., Chamorro M., Varmus H. E. Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: Demonstration by expression in vivo. J. Virol. 66:1992;5147-5151.
40. Paul W. E. Can the immune response control HIV infection? Cell. 82:1995;177-182.
41. Peifang S., Pira G. L., Fenoglio D., Harris S., Costa M. G., Venturino V., Dessi V., Layton G., Laman J., Huisman J. G., Manca F. Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies. Clin. Exp. Immunol. 97:1994;361-366.
42. Rasmussen L., Battles J. K., Ennis W. H., Nagashima K., Gonda M. A. Characterization of virus-like particles produced by a recombinant baculovirus containing thegag. Virology. 178:1990;435-451.
43. Ratner L., Fisher A., Jagodzinski L., Mitsuya P., Liou R.-S., Gallo R. C., Wong-Staal F. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses. 3:1987;57-69.
44. Rinaldo C., Huang X-L, Fan Z., Ding M., Beltz L., Panicali D., Mazzara G., Leibmann J., Cottrill M., Gupta P. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
45. Rowland-Jones S. L., Nixon D. F., Aldhous M. C., Gotch F., Ariyoshi K., Hallam N., Kroll J. S., Froebel K., McMichael A. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 341:1993;860-861.
46. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature (London). 327:1987;473-476.
47. Schirmbeck R., Bohm E., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Intervirology. 39:1996;111-119.
48. M. D. Summers, G. E. Smith, 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agric. Exp. St. College Station, TX.
49. Tobin G. J., Battles J. K., Rasmussen L., Gonda M. A. Assembly of recombinant retroviral Gag precursors into pseudovirions in the baculovirus-insect cell expression system. Molecular Virology. Methods in Molecular Genetics. 7:1995;Academic Press, Orlando. p. 237-253.
50. Tobin G. J., Nagashima K., Gonda M. A. Use of the particle-forming properties of the HIV Gag precursor for packaging additional viral epitopes into pseudovirions produced in the baculovirus-insect cell expression system. Intervirology. 39:1996a;40-48.
51. Tobin G. J., Nagashima K., Gonda M. A. Immunologic and ultrastructural characterization of human immunodeficiency virus type 1 pseudovirions containing Gag and Env precursor proteins engineered in insect cells. Methods: Companion Methods Enzymol. 10:1996b;208-218.
52. Wagner R., Deml L., Fliessbach H., Wanner G., Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology. 200:1994;162-175.
53. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 220:1996a;128-140.
54. Wagner R., Deml L., Notka F., Wolf H., Schirmbeck R., Reimann J., Teeuwesen V., Heeney J. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology. 39:1996b;93-103.
55. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (London). 328:1987;345-348.
56. Weber J., Cheinsong-Popov R., Callow D., Adams S., Patou G., Hodgkin K., Martin S., Gotch F., Kingsman A. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine. 13:1995;831-834.
57. Yamshchikov G. V., Ritter G. D., Vey M., Compans R. W. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology. 214:1995;50-58.